Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across disease stages. We aimed to analyze the current evidence and identify potential factors influencing response to therapies.

Methods

We conducted a systematic review of phase III RCTs (2002-2020) across disease stages. A meta-analysis was designed to examine the relationship between etiology and outcome after systemic therapies with either tyrosine-kinase inhibitor (TKI)/antiangiogenic or immune checkpoint inhibitor (ICI) therapy.

Results

Out of 10,100 studies identified, 76 were phase III RCTs. Among them, a rigorous scr

SUBMITTER: Haber PK 

PROVIDER: S-EPMC12276942 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature